194 related articles for article (PubMed ID: 24608435)
1. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.
Serasinghe MN; Missert DJ; Asciolla JJ; Podgrabinska S; Wieder SY; Izadmehr S; Belbin G; Skobe M; Chipuk JE
Oncogene; 2015 Feb; 34(7):857-67. PubMed ID: 24608435
[TBL] [Abstract][Full Text] [Related]
2. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
3. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens.
Anvekar RA; Asciolla JJ; Lopez-Rivera E; Floros KV; Izadmehr S; Elkholi R; Belbin G; Sikora AG; Chipuk JE
Cell Death Dis; 2012 Nov; 3(11):e420. PubMed ID: 23152056
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
[TBL] [Abstract][Full Text] [Related]
8. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.
Mukherjee N; Almeida A; Partyka KA; Lu Y; Schwan JV; Lambert K; Rogers M; Robinson WA; Robinson SE; Applegate AJ; Amato CM; Luo Y; Fujita M; Norris DA; Shellman YG
Oncotarget; 2016 Dec; 7(51):84594-84607. PubMed ID: 27829238
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
10. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Shao Y; Aplin AE
Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
12. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
14. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
16. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
17. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
18. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.
Gunda V; Sarosiek KA; Brauner E; Kim YS; Amin S; Zhou Z; Letai A; Parangi S
Cancer Lett; 2017 Jun; 395():1-10. PubMed ID: 28259821
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
Jiang CC; Lai F; Tay KH; Croft A; Rizos H; Becker TM; Yang F; Liu H; Thorne RF; Hersey P; Zhang XD
Cell Death Dis; 2010 Sep; 1(9):e69. PubMed ID: 21364673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
